Health outcomes (years) and costs for sunitinib-and pazopanib-initiating sequences.

NIAID Data Ecosystem2026-03-11 收录

数据链接：

https://figshare.com/articles/dataset/Health_outcomes_years_and_costs_for_sunitinib-and_pazopanib-initiating_sequences_/9749963 数据链接链接失效反馈

官方服务：

资源简介：

Health outcomes (years) and costs for sunitinib-and pazopanib-initiating sequences.

创建时间：

2019-08-29

Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease

药物经济学评估

血管疾病治疗

BACKGROUND: Low molecular weight heparins hold several advantages over unfractionated heparin including convenience of administration. Enoxaparin is one such heparin licensed in the UK for use in unst

PubMed Central2001-10-15 更新30

Table 1_Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis.docx

药物经济学评估

COVID-19治疗

IntroductionRemdesivir (RDV) and nirmatrelvir/ritonavir (NRM/RTV) are two antiviral agents for treating outpatient adults with mild to moderate symptomatic COVID-19 at high risk of developing a severe

NIAID Data Ecosystem10

Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands

药物经济学评估

结肠炎治疗

Aims: Budesonide with multi-matrix technology (MMX) is an oral corticosteroid, shown to have high topical activity against ulcerative colitis (UC) while maintaining low systemic bioavailability

Taylor & Francis Group2019-03-27 更新10

DataSheet_1_Determination of a cost-effectiveness threshold for cancer interventions in Iran.docx

疫苗卫生经济学评估

肿瘤治疗成本效益

Background and objectivesThe estimation of a cost- Effectiveness (CE) threshold from the perspective of those who have experienced a life-threatening disease can provide empirical evidence for health

NIAID Data Ecosystem20

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of multiple biologic agents-Switched.

药物经济学评估

类风湿关节炎治疗管理

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of multiple biologic agents-Switched.

Figshare2018-07-18 更新10

Health outcomes (years) and costs for sunitinib-and pazopanib-initiating sequences.

资源简介：

相关数据集